Lung Tumor RF Ablation Trials Should Assess Survival Benefit – FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Survival rates following lung tumor treatment with RITA Medical Systems' StarBurst radiofrequency (RF) ablation device should be assessed at one year, FDA's General & Plastic Surgery Devices Panel recommends